A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC). - SEARCH

• Register: EUCTR
• Last refreshed on: 25 March 2013
• Main ID: EUCTR2008-006021-14-IT
• Date of registration: 10/08/2009
• Prospective Registration: Yes
• Primary sponsor: Bayer HealthCare AG
• Public title: A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC). - SEARCH
• Scientific title: A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC). - SEARCH
• Date of first enrolment: 28/08/2009
• Target sample size: 700
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006021-14
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: yes Other: no

Countries of recruitment

Austria, Belgium, Bulgaria, France, Germany, Greece, Italy, Spain, United Kingdom

Key inclusion & exclusion criteria

Inclusion criteria:
> Patients with histological or cytologically documented HCC or clinical diagnosis by AASLD criteria in cirrhotic subjects is required. For subjects without cirrhosis histological confirmation is necessary. Patients must have at least one tumor lesions that meets both of the following criteria: - Lesion can be accurately measured in at least one dimension according to RECIST - Lesion has not been previously treated with local therapy (such as surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation Patients who have received local therapy are eligible. Local theapy must be completed at least 4 weeks prior to the baseline scan. Previously treated lesions will not be selected as target lesions. Patients with an ECOG PS of 0 or 1. Cirrhotic status of Child-Pugh Class A. Following Laboratory Parameters (as assessed by Central Laboratory): - Platelet count ≥ 60 x 109/L - Hemoglobin ≥ to 8.5 g/dl - Total Bilirubin ≤ 2.8 mg/dl - ALT and AST ≤ 5 x ULN - Serum Creatinine ≤ 1.5 x ULN - PT international normalized ration (INR) ≤ 2.3 or PT ≤ 6 seconds above control - Patients who are being therapeutically anticoagulated with an agent such as wafarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. Patients must provide written informed consent prior to any study procedures being performed
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Renal failure requiring hemo- or peritoneal dialysis Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) related illness or serious acute or chronic illness. Abnormalities of the cornea based on history (e.g. dry eye syndrome, Sogrens syndrome) including congenital abnormality (e.g. Fuchs dystrophy), abnormal slit-lamp examination using a vital dye (e.g. fluorescein, Bengal-Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test). Child-Pugh class B or C Previous treatment with yttrium- 90 spheres Clinically significant peripheral vascular disease History of cardiac disease: congestive heart failure > New York Heart Association (NYHA) class 2; active coronary artery disease (CAD); cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), or uncontrolled hypertension. Myocardial infarction more than 6 months prior to study entry is permitted. (See Appendix 10.7) History of interstitial lung disease (ILD) Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry Active clinically serious infections (> grade 2 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version 3.0), except HBV/HCV infections Uncontrolled ascites (defined as not easily controlled with diuretic treatment) Pregnant or breast-feeding patients.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

To evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotibib 150 mg once a day in subjects with unresectable advanced or metastatic Child-Pugh A HCC
MedDRA version: 9.1 Level: LLT Classification code 10019828
MedDRA version: 9.1 Level: LLT Classification code 10019829

Intervention(s)

Trade Name: NEXAVAR
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Sorafenib
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-

Trade Name: TARCEVA
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Erlotinib
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Primary Outcome(s)

Primary end point(s): Overall Survival measured via patient phone contacts after treatment is complete

Secondary Objective: Time to radiographic Tumor Progression (TTP) Disease Control Rate (DCR) Safety Health Related Quality of Life (HRQoL) and utility values as measured by EQ-5D

Main Objective: Overall Survival

Secondary ID(s)

2008-006021-14-DE

BAY 43-9006/12917